Arcturus Therapeutics (NASDAQ:ARCT) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.90 and traded as low as $7.10. Arcturus Therapeutics shares last traded at $7.72, with a volume of 907,435 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ARCT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st. B. Riley Financial started coverage on Arcturus Therapeutics in a research report on Wednesday, March 18th. They set a “buy” rating and a $22.00 price objective for the company. Wall Street Zen downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Piper Sandler decreased their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Finally, Citigroup lowered their price target on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Arcturus Therapeutics Price Performance

The firm has a market cap of $228.21 million, a PE ratio of -3.37 and a beta of 2.44. The stock has a 50-day moving average price of $7.38 and a 200 day moving average price of $9.87.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The business had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. As a group, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds have recently modified their holdings of ARCT. Hsbc Holdings PLC increased its position in Arcturus Therapeutics by 175.7% during the fourth quarter. Hsbc Holdings PLC now owns 66,131 shares of the biotechnology company’s stock worth $402,000 after purchasing an additional 42,148 shares during the last quarter. Aristides Capital LLC acquired a new position in shares of Arcturus Therapeutics in the 4th quarter valued at $161,000. Invesco Ltd. grew its stake in shares of Arcturus Therapeutics by 59.9% during the 4th quarter. Invesco Ltd. now owns 103,116 shares of the biotechnology company’s stock valued at $632,000 after buying an additional 38,626 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at $64,000. Finally, XTX Topco Ltd acquired a new stake in shares of Arcturus Therapeutics during the 4th quarter worth $504,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.